|
Demographics
| |
|
Age, years (range)
|
52 (30 to 80)
|
|
Sex, females/males
|
36/14
|
|
Smoking history, n (%)
| |
|
Current
|
8 (16)
|
|
Former
|
9 (18)
|
|
Never
|
33 (66)
|
|
Disease duration, months
|
4 (1 to 12)
|
|
Autoantibodies
| |
|
Rheumatoid factor (RF), no. positive (%)
|
30 (60)
|
|
Anti-CCP
|
39 (78)
|
|
RF or anti-CCP
|
42 (84)
|
|
Inflammatory indices
| |
|
Erythrocyte sedimentation rate (ESR), mm/h (range)
|
23 (3 to 98)
|
|
C-reactive protein (CRP), mg/L (range)
|
7.6 (0.2 to 118)
|
|
Disease activity
| |
|
DAS28-ESR
|
4.7 (1.6 to 8.1)
|
|
Tender joint count (TJC), n (range)
|
8 (0 to 26)
|
|
Swollen joint count (SJC), n (range)
|
3 (0 to 23)
|
|
Clinical Disease Activity Index (CDAI)
|
19.2 (2 to 57.7)
|
|
Health Assessment Questionnaire (HAQ)
|
0.35 (0 to 2.55)
|
|
Medications prior to study entry, n (%)
| |
|
Prednisone
|
13 (26)
|
|
Nonsteroidal anti-inflammatory drug (NSAID)
|
30 (60)
|
|
Methotrexate (MTX)
|
0
|
|
Tumor necrosis factor (TNF) inhibitor
|
0
|
